An FDA panel recommended the approval of a new Alzheimer's drug, donanemab, which slows cognitive decline. The drug, marketed as Kisunla, removes beta-amyloid plaques in the brain.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
An FDA panel recommended the approval of a new Alzheimer's drug, donanemab, which slows cognitive decline. The drug, marketed as Kisunla, removes beta-amyloid plaques in the brain.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.